Merck & Co.
AWARDS
NEWS
Vaccinex, a company developing a novel approach to treat both cancer and neurodegenerative disease through the inhibition of SEMA4D, will pair its lead asset with Merck’s vaunted checkpoint inhibitor Keytruda.
Merck is making a major investment into Bothwell, Washington-based Seattle Genetics with two strategic oncology deals.
It was a busy week for clinical trial updates. Here’s a look.
Merck, known as MSD outside of the U.S. and Canada, announced on Wednesday that it has seen positive results regarding the safety, tolerability and immunogenicity of V114 in two Phase III studies.
Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
JOBS
IN THE PRESS